Letters of Intent and Exclusivity in Distribution Deals

Before a distribution agreement is signed, most negotiations pass through two preliminary instruments: a letter of intent (LOI) and, frequently, a period of exclusivity. Both documents shape how the eventual contract gets negotiated, but they are routinely misread as either more binding or less binding than they actually are. For manufacturers and distributors structuring entry into a new market, knowing precisely what each instrument commits the parties to, and what it deliberately leaves open, prevents costly disputes once the real contract is drafted.

What a Letter of Intent Actually Does

An LOI is a document that records the parties' shared intention to negotiate toward a distribution agreement, typically setting out the proposed scope (territory, product lines, minimum volumes) and a timeline for reaching final terms. It is not, by itself, a distribution agreement. Its primary function is to give both sides enough confidence to invest time and resources, due diligence, regulatory filings, internal approvals, before a fully negotiated contract exists. Because an LOI is often drafted quickly and informally relative to the final agreement, the specific wording used for each clause matters more than the document's label.

Binding vs Non-Binding Provisions

The most consequential drafting decision in an LOI is which clauses are binding and which are not. Commercial terms (pricing, volume targets, the final contract's duration) are usually stated as non-binding, meaning either party can walk away without breach if those terms change during negotiation. Certain provisions, however, are commonly made binding regardless of whether the deal closes: confidentiality obligations, a no-shop or exclusivity-of-negotiation clause, allocation of due-diligence costs, and the governing law and dispute-resolution mechanism for the LOI itself. A document that fails to separate these two categories clearly is a frequent source of later disagreement about what was actually promised.

| Provision type | Typically binding? | Why | |---|---|---| | Pricing, volumes, contract duration | No | Subject to final negotiation | | Confidentiality | Yes | Protects shared information regardless of outcome | | Exclusivity of negotiation | Often yes | Gives the party exclusivity something to rely on | | Governing law for the LOI | Yes | Needed to resolve disputes about the LOI itself |

Exclusivity Clauses: Scope, Duration and Carve-Outs

An exclusivity clause in an LOI or early-stage agreement restricts one or both parties from negotiating with, or supplying to, other counterparts within a defined territory, product category and time window. For a manufacturer, granting exclusivity to a prospective distributor before a full agreement is signed is a meaningful commitment, since it forecloses other opportunities in that market for the duration. For this reason, exclusivity periods are typically kept short and tied to specific milestones (completion of due diligence, regulatory filing, a target signing date) rather than left open-ended. Well-drafted exclusivity clauses also specify carve-outs, existing customers, other product lines, or a right to terminate exclusivity if negotiation milestones are missed, so that the restriction does not outlast its purpose.

Common Pitfalls in Drafting

Several recurring issues surface in LOI and exclusivity negotiations for medical device and pharmaceutical distribution. An LOI silent on what happens if the final agreement is never reached can leave sunk due-diligence costs unallocated. An exclusivity period without a defined end date or exit trigger can tie up a manufacturer's market access indefinitely while talks stall. And a "non-binding" LOI that nonetheless creates detailed, specific commercial expectations can, in some jurisdictions, support a claim that the parties intended some obligations to be enforceable despite the label. Distributors and manufacturers typically have counsel review both the labeled intent of each clause and its practical effect, since the two do not always align.

Why This Stage Matters for Procurement Timelines

For institutional buyers and distributors planning market entry, the LOI and exclusivity stage is not a formality to rush through. The milestones set here, due diligence completion, regulatory submission dates, exclusivity expiry, often determine the realistic timeline for when product can actually move, independent of how quickly the final distribution agreement itself gets drafted. Treating this stage with the same discipline as the eventual contract tends to shorten, not lengthen, the overall path to a signed, workable agreement.

The Takeaway

A letter of intent and an exclusivity clause are tools for structuring negotiation, not substitutes for the distribution agreement itself. Clarity about which provisions bind the parties immediately, how exclusivity is scoped and time-limited, and what happens if talks do not conclude, is what keeps this preliminary stage from becoming a source of dispute later.

This is general educational information, not legal or regulatory advice; consult the current official texts and your competent authority.